Stevanato
No price chart data available for 1D timeframe.
Rating
Key Statistics
Market Data
Valuation (TTM)
Valuation (NTM)
Cash Flow
Margins
Growth (CAGR)
Returns
Financial Health
Dividends
Profile
Stevanato Group S.p.A. is dedicated to engineering, manufacturing, and distributing integrated solutions for the pharmaceutical and healthcare sectors. Its core offerings span a wide array of products...
Latest News
16 hours ago · gurufocus.com
Stevanato Group to Participate in Upcoming Investor Conferences[url="]Stevanato Group S.p.A.[/url] (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical,
13 days ago · globenewswire.com
Stevanato Group (STVN) Shareholder Investigation Following Stock Decline – Kehoe Law Firm, P.C.Kehoe Law Firm, P.C. is investigating potential securities claims on behalf of Stevanato Group (STVN) investors following the Company's stock price decline
13 days ago · marketbeat.com
Stevanato Group Q3 Earnings Call HighlightsStevanato Group NYSE: STVN reported third-quarter 2026 revenue growth of 8% to €326.1 million, supported by continued expansion in its biopharmaceutical and diagnostic solutions business despite weaker demand tied to GLP-1 therapies and a decline in its engineering segment.
13 days ago · prnewswire.com
Stevanato Group S.p.A. Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into Stevanato Group S.p.A.STVN shares fell on November 3, 2026, as the market reacted to a lower GLP-1 revenue outlook in Stevanato Group's pre-market third-quarter results, the issue previews had flagged as the quarter's key test. SueWallSt notifies investors of a pending investigation into whether the Company's disclosures to investors met U.S. securities law requirements.
13 days ago · seekingalpha.com
Stevanato Group S.p.A. (STVN) Q3 2026 Earnings Call TranscriptStevanato Group S.p.A. ( STVN ) Q3 2026 Earnings Call November 3, 2026 8:30 AM EST Company Participants Lisa Miles - Chief Communications & Investor Relations Officer Franco Stevanato - CEO & Executive Chairman Marco Dal Lago - Chief Financial Officer Conference Call Participants David Windley - Jefferies LLC, Research Division Avantika Dhabaria - BofA Securities, Research Division Anna Snopkowski - KeyBanc Capital Markets Inc., Research Division Chad Wiatrowski - TD Cowen, Research Division Lawrence Solow - CJS Securities, Inc. Steven Etoch - Stephens Inc., Research Division Douglas Schenkel - UBS Investment Bank, Research Division Curtis Moiles - BNP Paribas, Research Division Albert Hu - Citigroup Inc., Research Division Justin Bowers - Deutsche Bank AG, Research Division Presentation Operator Good afternoon.
14 days ago · zacks.com
Stevanato Group (STVN) Surpasses Q3 Earnings and Revenue EstimatesStevanato Group (STVN) came out with quarterly earnings of $0.18 per share, beating the Zacks Consensus Estimate of $0.17 per share. This compares to earnings of $0.16 per share a year ago.
14 days ago · businesswire.com
Stevanato Group Delivers 8% Revenue Growth for the Third Quarter of Fiscal 2026PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, today announced its financial results for the third quarter of 2026. Third Quarter of 2026 Highlights (comparisons to prior-year period) Revenue increased 8% to €326.1 million, and on an organic basis* revenue increased 8%. Revenue from high-value solutions represente.
21 days ago · seekingalpha.com
Conestoga Small Cap Composite Q3 2026 Portfolio ActivityThe Conestoga Small Cap Composite returned -11.22% net of fees in 3Q26, trailing the -9.39% return for the Russell 2000 Growth Index. Small Cap Composite top 5 leaders include Repligen, Merit Medical, Stevanato Group, Descartes Systems and Digi International. Small Cap Composite bottom 5 laggards include Mercury Systems, AAON, RBC Bearings, SPX Technologies and UL Solutions.
21 days ago · businesswire.com
Stevanato Group and Aptar Pharma Collaborate to Help Accelerate Pre-Filled Syringe System SelectionPIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN) (the “Company”), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, today announced a collaboration with Aptar Pharma to provide system-level data supporting earlier evaluation of pre-filled syringe configurations for biotech and pharmaceutical companies, with a focus on sensitive biologics and other injectable therapie.
27 days ago · businesswire.com
Stevanato Group to Report Third Quarter 2026 Financial Results on November 3, 2026PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, announced today that it will issue financial results for the third quarter of 2026 on Tuesday, November 3, 2026, at 6:30 a.m. (EDT). Conference call and webcast: The Company will host a conference call and webcast at 8:30 a.m. (EDT) on Tuesday, November 3, 2026, to di.
Earnings
Analyst Summary
Add to Watchlist
Select watchlists to add or remove STVN